THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

FDA panel rejects sales of Mevacor over counter

By Diedtra Henderson
Globe Staff / January 15, 2005

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size – +

Federal advisers rejected Merck & Co.'s quest to become the first American drug maker to sell cholesterol-fighting statins over the counter, saying the company's own studies raised potential health risks while offering modest life-saving benefits. (Full article: 814 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 article
  • $9.95 4 articles
  • $25.95 Monthly